AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24171782 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint control group, 20 sessions over four weeks.
Number of subjects: 249
Study 24171782 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group, no treatment for 24 weeks, followed by 20 acupuncture treatments for free.
Number of subjects: 249
Study 21380966 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative loading (NLG)
Number of subjects: 32
Study 21380966 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive loading (PLG)
Number of subjects: 32
Study 21380966 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 18312057 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day for 10 weeks
Number of subjects: 19
Study 18312057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18312057 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 19
Study 17025273 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, subcutaneous doses of 0.5 microg/kg every week to 15 microg/kg every 3 weeks
Number of subjects: 573
Study 17025273 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, intravenous and subcutaneous doses of 2.25 microg/kg every week and 6.75 microg/kg every 3 weeks
Number of subjects: 573
Study 17025273 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, subcutaneous doses
Number of subjects: 573
Study 17025273 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 573
Study 12958395 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance
Number of subjects: 12
Study 12958395 — intervention group
Group type: COMPARATOR
Intervention: Own brand
Number of subjects: 12
Study 12958395 — intervention group
Group type: COMPARATOR
Intervention: No cigarettes
Number of subjects: 12
Study 10945387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusions of 1,000 IU AT III every 4 h for 4 days (total dose: 30,000 IU AT III)
Number of subjects: 33
Study 10945387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 250 IU AT III/h for 4 days (total dose: 30,000 IU AT III)
Number of subjects: 33
Study 10945387 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (Intermittent bolus and Continuous infusion)
Number of subjects: 33
Study 8930434 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin (Cerebyx)
Number of subjects: 52
Study 8930434 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (Dilantin)
Number of subjects: 52
Study 1532964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium succinate ointment (8%)
Number of subjects: 227
Study 1532964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 3902527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (24 h prophylaxis)
Number of subjects: 206
Study 3902527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 3902527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (48 h prophylaxis)
Number of subjects: 206
Study 31000320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement with HMB 1200mg, l‐glutamine 7000mg, and l‐arginine 7000mg administered once or twice per day for 14‐28 days preoperatively.
Number of subjects: 0
Study 31000320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 0
Study 29095655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (9 strengthening and 9 stretching exercises, performed during warm-up or at home)
Number of subjects: 305
Study 29095655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 305
Study 29095655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 305
Study 27465872 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intracavitary irradiation (PII)
Number of subjects: 133
Study 27465872 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 133
Study 27465872 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy (RH)
Number of subjects: 133
Study 25369857 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation and alcohol intervention
Number of subjects: 1350
Study 25369857 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation only intervention
Number of subjects: 1350
Study 22355008 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Stroop‐like token task with increased WMC demands
Number of subjects: 32
Study 19789375 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 18603157 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the intervention (nurse-delivered complex intervention)
Number of subjects: 200
Study 18603157 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study 18603157 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the intervention
Number of subjects: 200
Study 16048622 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Case Discussion (FCD)
Number of subjects: 46
Study 16048622 — intervention group
Group type: COMPARATOR
Intervention: Computerised Tutorial (CT)
Number of subjects: 46
Study 12805389 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month weight-loss program including 10 weeks on a very-low-energy diet (VLED) and 17 behavior modification visits
Number of subjects: 38
Study 12805389 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 38
Study 10192481 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 200
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: isoproterenol
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 20
Study 8531105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: atropine
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: norepinephrine
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 20
Study 8531105 — intervention group
Group type: EXPERIMENTAL
Intervention: adenosine
Number of subjects: 20
Study 1708969 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/24 h in three divided doses)
Number of subjects: 35
Study 1708969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 389978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 389978 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 389978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31437228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS-based staff training
Number of subjects: 63
Study 28712681 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 199
Study 28712681 — intervention group
Group type: COMPARATOR
Intervention: Usual job search advice (Control)
Number of subjects: 199
Study 25475116 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nitisinone
Number of subjects: 40
Study 25475116 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nitisinone
Number of subjects: 40
Study 25475116 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nitisinone
Number of subjects: 40
Study 25475116 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nitisinone
Number of subjects: 40
Study 25475116 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 24908550 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group)
Number of subjects: 439
Study 24908550 — intervention group
Group type: COMPARATOR
Intervention: NNRTI plus emtricitabine and tenofovir (no-switch group)
Number of subjects: 439
Study 22226170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 303
Study 22226170 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (TFA)
Number of subjects: 303
Study 18622618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral rotational keratoplasty (IRK) and cataract extraction
Number of subjects: 17
Study 18622618 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative spherical refraction
Number of subjects: 17
Study 18622618 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled keratitis
Number of subjects: 17
Study 17488502 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training 3x/week over a 7-week period for high-risk athletes
Number of subjects: 24
Study 17488502 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 subjects classified as high-risk and 7 classified as low-risk)
Number of subjects: 24
Study 17488502 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training for low-risk athletes
Number of subjects: 24
Study 15008864 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 20
Study 11591618 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin I (Ang I)
Number of subjects: 0
Study 11591618 — intervention group
Group type: EXPERIMENTAL
Intervention: [Pro(11)(D)‐Ala(12)] Ang I
Number of subjects: 0
Study 11591618 — intervention group
Group type: COMPARATOR
Intervention: Captopril (6.25 mg oral dose)
Number of subjects: 0
Study 11591618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9723821 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 44
Study 9723821 — intervention group
Group type: EXPERIMENTAL
Intervention: piroxicam 20 mg
Number of subjects: 44
Study 9723821 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 7849250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 100 mg/day
Number of subjects: 24
Study 7849250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7849250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg thrice daily added to thiazide and placebo regimens
Number of subjects: 24
Study 2974770 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria based on chest lead voltages
Number of subjects: 100
Study 2974770 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria based on limb lead voltages
Number of subjects: 100
Study 2974770 — intervention group
Group type: EXPERIMENTAL
Intervention: All electrocardiographic criteria
Number of subjects: 100
Study 29383503 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Synovectomy (TS)
Number of subjects: 148
Study 29383503 — intervention group
Group type: COMPARATOR
Intervention: Limited Synovectomy
Number of subjects: 148
Study 27156189 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg once daily for 3 days
Number of subjects: 754
Study 27156189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754
Study 27156189 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 754
Study 27156189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 754
Study 24595224 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated arabinoxylan combined with rye kernels (AXRK)
Number of subjects: 15
Study 24595224 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated arabinoxylan (AX)
Number of subjects: 15
Study 24595224 — intervention group
Group type: COMPARATOR
Intervention: Control meal (semolina porridge, SE)
Number of subjects: 15
Study 22008873 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab
Number of subjects: 0
Study 22008873 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab + IFNβ‐1a
Number of subjects: 0
Study 20473070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 40
Study 20473070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17851902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ménière's disease group
Number of subjects: 20
Study 17851902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 16547387 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus group
Number of subjects: 60
Study 12381983 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia (MUA)
Number of subjects: 87
Study 12381983 — intervention group
Group type: COMPARATOR
Intervention: Traditional chiropractic treatment (nonintervention group)
Number of subjects: 87
Study 8536868 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments for inflammatory bowel disease (specific interventions not detailed in the abstract)
Number of subjects: 0
Study 8536868 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials methodology
Number of subjects: 0
Study 2180981 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human GH treatment
Number of subjects: 30
Study 2180981 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 2180981 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for acromegaly
Number of subjects: 30
Study 543202 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day Perhexilinmaleat
Number of subjects: 15
Study 543202 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day Perhexilinmaleat
Number of subjects: 15
Study 543202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31021278 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot (BR) juice supplementation
Number of subjects: 8
Study 31021278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) juice
Number of subjects: 8
Study 28364270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 28364270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 28364270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bisoprolol and ramipril
Number of subjects: 0
Study 28364270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25633470 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying Phonation Intervals (MPI) treatment
Number of subjects: 27
Study 25633470 — intervention group
Group type: COMPARATOR
Intervention: Prolonged speech treatment
Number of subjects: 27
Study 23989747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative expectations of improvement in pain and health status measured using 100 mm visual analogue scales (VAS)
Number of subjects: 0
Study 23989747 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative satisfaction ratings using 100 mm VAS
Number of subjects: 0
Study 23989747 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance attached to recovery
Number of subjects: 0
Study 23989747 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in achieving expected results
Number of subjects: 0
Study 20082130 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral intervention
Number of subjects: 819
Study 20082130 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 819
Study 19595803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration and sclerotherapy
Number of subjects: 60
Study 19595803 — intervention group
Group type: COMPARATOR
Intervention: Hydrocelectomy
Number of subjects: 60
Study 17987114 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% dimeticone lotion
Number of subjects: 73
Study 17987114 — intervention group
Group type: COMPARATOR
Intervention: 0.5% malathion liquid
Number of subjects: 73
Study 15188980 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) 5 ml
Number of subjects: 81
Study 15188980 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW) 5 ml (placebo)
Number of subjects: 81
Study 11480129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos), specific dosage and duration not mentioned
Number of subjects: 0
Study 10452408 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter oil and low erucic rapeseed oil (65:35) (BR)
Number of subjects: 13
Study 10452408 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter blended in a 1:1 ratio with an interesterified mixture of rapeseed oil and fully hydrogenated rapeseed oil (70:30) (BS)
Number of subjects: 13
Study 10452408 — intervention group
Group type: COMPARATOR
Intervention: Butter/grapeseed oil (90:10) (BG)
Number of subjects: 13
Study 7645110 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 7645110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved disease‐free survival of poor‐prognosis subgroups
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Better chemotherapy regimens and bone marrow transplantation
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening of therapy duration
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization between staging systems
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable application and interpretation of multivariate analysis
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger patient numbers in clinical studies
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable in vitro tests of chemosensitivity and chemoresistance
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitation of residual leukemia after remission induction
Number of subjects: 0
Study 2694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of optimum therapy and supportive care
Number of subjects: 0
Study 1107612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (35%)
Number of subjects: 111
Study 31811674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care intervention
Number of subjects: 52
Study 31811674 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study 30388950 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mindfulness practice (daily using an audio CD)
Number of subjects: 72
Study 30388950 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 28637246 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (0.215 mg/kg p.o.)
Number of subjects: 32
Study 28637246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25887140 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily
Number of subjects: 186
Study 25887140 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 186
Study 23743754 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based balance rehabilitation program (12 sessions)
Number of subjects: 44
Study 23743754 — intervention group
Group type: COMPARATOR
Intervention: Betahistine and diet (Control group)
Number of subjects: 44
Study 21088592 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP-guided anaesthesia (group A)
Number of subjects: 450
Study 21088592 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 450
Study 19741494 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (80 microg)
Number of subjects: 43
Study 19741494 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (10 mg)
Number of subjects: 43
Study 19741494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus phenylephrine (80 microg)
Number of subjects: 43
Study 19741494 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 43
Study 16500392 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab (3 doses)
Number of subjects: 0
Study 16500392 — intervention group
Group type: COMPARATOR
Intervention: Episodic treatment with infliximab (single dose)
Number of subjects: 0
Study 16500392 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab
Number of subjects: 0
Study 16500392 — intervention group
Group type: COMPARATOR
Intervention: Episodic treatment with infliximab
Number of subjects: 0
Study 16500392 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled infliximab maintenance therapy
Number of subjects: 0
Study 16500392 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 15624081 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/day
Number of subjects: 115
Study 15624081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 11716203 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of prednisolone p.o. for 1 week
Number of subjects: 43
Study 11716203 — intervention group
Group type: COMPARATOR
Intervention: 1600 microg of inhaled budesonide daily for 1 week
Number of subjects: 43
Study 11716203 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 microg of inhaled budesonide daily for 3 weeks (after initial treatment)
Number of subjects: 43
Study 11716203 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between deltaFEV1 and eosinophil markers after 4 weeks
Number of subjects: 43
Study 9386066 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 152
Study 9386066 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 152
Study 7606644 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on a treadmill for 1.5 h at 40% of maximal oxygen uptake, starting 1.5 h after the meal
Number of subjects: 12
Study 7606644 — intervention group
Group type: COMPARATOR
Intervention: Resting for 6 h after consuming the meal
Number of subjects: 12